VALIDATION OF THE REVISED 2017 EUROPEAN LEUKEMIANET GENETIC RISK STRATIFICATION FOR AML
In 2010, the European LeukemiaNet (ELN) guidelines introduced a genetic risk stratification to facilitated a better diagnosis and management of adult acute myeloid leukaemia (AML) patients. In 2017., these guidelines were updated to include an updated genetic risk stratification system incorporating additional cytogenetic and molecular prognostic factors. The updated guidelines have been widely adopted, but remain to be validated in large cohorts of AML patients…
FLUMATINIB INDUCES HIGHER RATES OF DEEP RESPONSES COMPARED TO IMATINIB IN NEWLY DIAGNOSED, CHRONIC PHASE, CML
Results of a randomized phase III trial (FESTnd) demonstrate that the novel BCR-ABL1 tyrosine kinase inhibitor flumatinib is associated with higher response rates than imatinib in the first line treatment of CML-CP patients. Responses to flumatinib also occurred significantly faster and more patients obtained deep responses with this novel agent compared to imatinib...
REDUCED-INTENSITY THERAPY OF PAEDIATRIC LYMPHOBLASTIC LEUKAEMIA
Results of an Egyptian study indicate that children with very low risk (VLR) acute lymphoblastic leukemia (ALL) can successfully be treated with decreased-intensity therapy. Moreover, the study underscores that the classification criteria for VLR can be further refined by using a more sensitive assay assessing minimal residual disease (MRD)...
PANOBINOSTAT PLUS SUBCUTANEOUS BORTEZOMIB AND ORAL DEXAMETHASONE FOR PATIENTS WITH R/R MULTIPLE MYELOMA
Data from the phase II PANORAMA-3 trial suggest that a subcutaneous administration of bortezomib improves the tolerability of the panobinostat-bortezomib-dexamethasone triplet in patients with relapsed/refractory multiple myeloma (RRMM). In this trial, three different doses of panobinostat were tested of which the 20 mg three or two times weekly were associated with the highest response rate. In contrast, panobinostat at a dose of 10 mg three times per week was best tolerated…
CLINICAL CHARACTERISTICS AND OUTCOMES OF EXTRANODAL STAGE I DIFFUSE LARGE B CELL LYMPHOMA IN THE RITUXIMAB-ERA
Results of a large retrospective study confirm the excellent outcome of patients with stage I diffuse large B-cell lymphoma (DLBCL) in the R-CHOP era. This was especially pronounced in patients with nodal disease. Extranodal stage I DLBCL patients had a slightly worse outcome and the optimal number of chemotherapy cycles for these patients remains to be elusive. Similarly, also the role for RT in extranodal patients remains unclear…
Top
